These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


217 related items for PubMed ID: 21928824

  • 1. Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41.
    Zhou G, Wu D, Snyder B, Ptak RG, Kaur H, Gochin M.
    J Med Chem; 2011 Oct 27; 54(20):7220-31. PubMed ID: 21928824
    [Abstract] [Full Text] [Related]

  • 2. Structure-activity relationship studies of indole-based compounds as small molecule HIV-1 fusion inhibitors targeting glycoprotein 41.
    Zhou G, Sofiyev V, Kaur H, Snyder BA, Mankowski MK, Hogan PA, Ptak RG, Gochin M.
    J Med Chem; 2014 Jun 26; 57(12):5270-81. PubMed ID: 24856833
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41.
    Zhou G, Wu D, Hermel E, Balogh E, Gochin M.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1500-3. PubMed ID: 20153190
    [Abstract] [Full Text] [Related]

  • 4. Investigation of the molecular characteristics of bisindole inhibitors as HIV-1 glycoprotein-41 fusion inhibitors.
    Zhou G, Chu S, Nemati A, Huang C, Snyder BA, Ptak RG, Gochin M.
    Eur J Med Chem; 2019 Jan 01; 161():533-542. PubMed ID: 30390441
    [Abstract] [Full Text] [Related]

  • 5. Development of HIV-1 fusion inhibitors targeting gp41.
    Lu K, Asyifah MR, Shao F, Zhang D.
    Curr Med Chem; 2014 Jun 01; 21(17):1976-96. PubMed ID: 24350848
    [Abstract] [Full Text] [Related]

  • 6. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
    Jiang S, Lu H, Liu S, Zhao Q, He Y, Debnath AK.
    Antimicrob Agents Chemother; 2004 Nov 01; 48(11):4349-59. PubMed ID: 15504864
    [Abstract] [Full Text] [Related]

  • 7. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
    An T, Ouyang W, Pan W, Guo D, Li J, Li L, Chen G, Yang J, Wu S, Tien P.
    Antiviral Res; 2012 Jun 01; 94(3):276-87. PubMed ID: 22426469
    [Abstract] [Full Text] [Related]

  • 8. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L.
    J Virol; 2017 Jan 01; 91(1):. PubMed ID: 27795416
    [Abstract] [Full Text] [Related]

  • 9. Paramagnetic relaxation assisted docking of a small indole compound in the HIV-1 gp41 hydrophobic pocket.
    Gochin M, Zhou G, Phillips AH.
    ACS Chem Biol; 2011 Mar 18; 6(3):267-74. PubMed ID: 21155611
    [Abstract] [Full Text] [Related]

  • 10. Conformational flexibility of the conserved hydrophobic pocket of HIV-1 gp41. Implications for the discovery of small-molecule fusion inhibitors.
    Cano-Muñoz M, Jurado S, Morel B, Conejero-Lara F.
    Int J Biol Macromol; 2021 Dec 01; 192():90-99. PubMed ID: 34619276
    [Abstract] [Full Text] [Related]

  • 11. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L, Gochin M, Liu K.
    Curr Top Med Chem; 2011 Dec 01; 11(24):2959-84. PubMed ID: 22044229
    [Abstract] [Full Text] [Related]

  • 12. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.
    Yu F, Lu L, Du L, Zhu X, Debnath AK, Jiang S.
    Viruses; 2013 Jan 11; 5(1):127-49. PubMed ID: 23344560
    [Abstract] [Full Text] [Related]

  • 13. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains.
    Lu L, Pan C, Li Y, Lu H, He W, Jiang S.
    Retrovirology; 2012 Dec 07; 9():104. PubMed ID: 23217195
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and biological evaluation of water-soluble derivatives of chiral gossypol as HIV fusion inhibitors targeting gp41.
    Yang J, Li LL, Li JR, Yang JX, Zhang F, Chen G, Yu R, Ouyang WJ, Wu SW.
    Bioorg Med Chem Lett; 2018 Jan 01; 28(1):49-52. PubMed ID: 29162455
    [Abstract] [Full Text] [Related]

  • 15. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
    Zhu Y, Ding X, Yu D, Chong H, He Y.
    J Virol; 2019 Dec 12; 94(1):. PubMed ID: 31619552
    [Abstract] [Full Text] [Related]

  • 16. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y, Chong H, Qiu Z, Xiong S, He Y.
    J Virol; 2015 Jun 12; 89(11):5801-11. PubMed ID: 25787278
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41.
    Jiang S, Tala SR, Lu H, Zou P, Avan I, Ibrahim TS, Abo-Dya NE, Abdelmajeid A, Debnath AK, Katritzky AR.
    Bioorg Med Chem Lett; 2011 Nov 15; 21(22):6895-8. PubMed ID: 21978673
    [Abstract] [Full Text] [Related]

  • 18. Amphipathic properties of HIV-1 gp41 fusion inhibitors.
    Gochin M, Zhou G.
    Curr Top Med Chem; 2011 Dec 15; 11(24):3022-32. PubMed ID: 22044226
    [Abstract] [Full Text] [Related]

  • 19. An effective conjugation strategy for designing short peptide-based HIV-1 fusion inhibitors.
    Liang G, Wang H, Chong H, Cheng S, Jiang X, He Y, Wang C, Liu K.
    Org Biomol Chem; 2016 Aug 16; 14(33):7875-82. PubMed ID: 27454320
    [Abstract] [Full Text] [Related]

  • 20. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG, Jia QY, Liu KL.
    Yao Xue Xue Bao; 2010 Feb 16; 45(2):184-93. PubMed ID: 21351428
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.